眼内出血
眼内出血的相关文献在1982年到2022年内共计102篇,主要集中在眼科学、中国医学、预防医学、卫生学
等领域,其中期刊论文97篇、会议论文1篇、专利文献5011篇;相关期刊62种,包括中华实用中西医杂志、中华眼外伤职业眼病杂志、中国实用眼科杂志等;
相关会议1种,包括全国中医、中西医结合眼科学术交流会等;眼内出血的相关文献由178位作者贡献,包括陈国秀、任征、宋敏等。
眼内出血
-研究学者
- 陈国秀
- 任征
- 宋敏
- 年春志
- 王万枝
- 王桂英
- 邓亚平
- Bueno C.L.
- Costen M.T.J
- Fledelius H.C.
- Fuller I.B.
- Maguluri S.
- Newsom R.S
- Wainwright A.C
- 丁哲
- 丁昌太
- 严宇清
- 于俊云
- 于滨
- 付玉芳
- 何为民
- 侯典根
- 侯柯
- 刘克非
- 刘大文
- 刘建东
- 刘涛媛
- 刘金兰
- 刘鑫
- 史亚文
- 叶存喜
- 叶绍熙
- 吴作仲
- 吴南莹
- 吴建明
- 吴彤霞
- 吴秀云
- 吴长鸿
- 周卫亚
- 周奉建
- 唐代陶
- 夏丽英
- 孙秀娥
- 孟乐
- 孟利娟
- 宋梦菊
- 尹英
- 岳旺
- 崔丽红
- 康美兰
-
-
刘建东;
高磊;
朱方兴;
李子旭
-
-
摘要:
患者,男,47岁,2018年11月21日因头痛、咽痛8 d于当地医院就诊,经骨髓活检及免疫组织化学、骨髓细胞形态学检查、骨髓染色体及核型分析等相关检查,确诊为急性早幼粒细胞白血病(acute promyelocyte leukemia,APL),给予亚砷酸、柔红霉素联合全反式维甲酸(all-trans retinoic acid,ATRA)化疗后5 d,诉双眼视力突然下降,经眼科会诊确诊为双眼玻璃体积血,考虑到患者全身情况差,白细胞28.90×10^(9)/L,红细胞1.88×10^(12)/L,血红蛋白63.0g/L,血小板13×10^(9)/L,双眼暂未予治疗。
-
-
-
陈源;
徐明;
邢茜;
陆炯
-
-
摘要:
目的 评估服用华法林(warfarin)对白内障晶状体超声乳化手术安全性的影响.方法 排除凝血酶原国际标准化比率(INR》 >3.0的91例(94眼)分为3组:A组33例(33眼)无心血管疾病史为对照组,B组28例(30眼)为术前暂停服用华法林组,C组30例(31眼)为不停用华法林组.对各组术中、术后眼内出血发生率进行比较.结果 各组所有手术均顺利完成,术中及术后均无眼内出血.结论 在INR <3.0情况下,不停用华法林仍可安全施行白内障超声乳化手术.%Objective To evaluate the safety of taking warfarin in phacoemulsification surgery for patients with cartaract.Methods The patients of prothrombin international normalized ratio (INR) > 3.0 were ruled out according to the exclusive criteria.Ninty-four eyes of 91 patients were divided into group A,B and C.Group A,33 eyes of 33 cases without history of cardiovascular clisease ware control group;group B,30 eyes of 28 cases were suspended taking warferin before surgery;group C,31 eyes of 30 cases received surgeries and took warferin continuously.Incidence of intraocular hemorrhages intraoperative and postoperative were compared among three groups.Results All surgeries were successfully performed.No intraocular hemorrhage occurred among three groups during and after operation.Conclusion Phacoemulsification could be safely performed without discontinuing warfarin in the case of prothrombin INR < 3.0.
-
-
徐泽强
-
-
摘要:
目的分析采用中医辨证治疗眼内出血的临床效果.方法:选取2014 年11 月至2015 年11 月期间我院眼科收治的眼内出血患者42 例,将其作为本次研究对象,给予其中医辨证治疗,分析治疗后的效果.结果:本次42 例眼内出血患者经治疗后,显效19 例(45.24%)、有效21 例(50.00%)、无效2 例(4.76%),总有效率为95.24%.结论:采用中医辨证治疗眼内出血的临床效果显著,值得进一步推广.
-
-
-
李秀兰;
樊全治;
孟乐
-
-
摘要:
目的:探讨中西医结合治疗外伤性眼内出血的临床效果。方法47例(52眼)外伤性眼内出血患者,采用中医结合治疗,观察治疗效果。结果47例(52眼)患者,治愈38眼,有效10眼,无效4眼。治疗效果满意,患者出血吸收,视力提高。结论中西医结合治疗外生性眼内出血根据出血的时间和部位采取不同的治疗方法疗效确切,值得推广。%Objective To investigate the treatment method and result of integrated traditional Chinese and western medicine in the treatment of intraocular hemorrhage.Methods Selected 47 cases(52 eyes) of traumatic intraocular hemorrhage as research objects, all treated by integrated traditional Chinese and western medicine, treatment effect was observed.Results All 47 cases(52 eyes), 38 eyes were cured, 10 eyes effective, 4 eyes ineffective, the treatment effect was good, hemorrhage absorbed, visual acuity improved.Conclusion Integrated traditional Chinese and western medicine in the treatment of intraocular hemorrhage has a good effect according to the time and location of hemorrhage with different methods, so it is worthy of clinical promotion.
-
-
吴作仲
-
-
摘要:
Objective:Investigate the non-penetrating ocular trauma causes secondary glaucoma and treatment methods.Methods:32 patients (32 eyes)after non-penG etrating ocular trauma causes secondary glaucoma and treatment were analyzed retrospectively.Result:Non-penetrating ocular trauma secondary glaucoma occurring after the main reasons:Intraocular hemorrhage 26 cases (81 .25 %)、Angle contusion 4 cases (1 2.50%)、Crystal- derived 2 cases (6 .25 %).Take on different causes different treatment.Conclusion:Non-penetrating ocular trauma causes secondary glaucoma after more complex,For each case should be based on the cause take specific targeted therapies.%目的:探讨非穿通性眼外伤后继发性青光眼的原因和治疗方法.方法:对32例(32眼)非穿通性眼外伤后继发性青光眼的原因及治疗进行回顾性分析.结果:非穿通性眼外伤后发生的继发性青光眼最主要的原因有:眼内出血26例(81.25%)、房角挫伤4例(12.50%)、晶体源性2例(6.25%).对不同的病因采取不同的治疗方法.结论:非穿通性眼外伤后继发性青光眼的原因较复杂,对每个病例应根据病因采取具体有针对性的治疗方法.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- 陈国秀
- 公开公告日期:1998-07-01
-
摘要:
本发明公开了一种治疗眼内出血的中成药—活血胶囊,它由参三七、川芎、丹参、大蓟、当归、赤芍、生地、芳根、双花、黄芩、石决明组成,经水提取法提出有效成分后,浓缩成膏,粉碎过筛,装入胶囊。本发明疗程短,疗效高,易于制造存贮,便于使用推广。